+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycystic Ovarian Syndrome - Pipeline Review, H2 2020

  • ID: 5174772
  • Drug Pipelines
  • September 2020
  • Region: Global
  • 55 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • Arkay Therapeutics LLC
  • Bayer AG
  • Cadila Healthcare Ltd
  • EffRx Pharmaceuticals SA
  • Spruce Biosciences Inc
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2020, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Ovarian Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Ovarian Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Arkay Therapeutics LLC
  • Bayer AG
  • Cadila Healthcare Ltd
  • EffRx Pharmaceuticals SA
  • Spruce Biosciences Inc
  • MORE
Introduction
  • Report Coverage
Polycystic Ovarian Syndrome - Overview

Polycystic Ovarian Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Polycystic Ovarian Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Arkay Therapeutics LLC
  • Bayer AG
  • BioRestorative Therapies Inc
  • Cadila Healthcare Ltd
  • EffRx Pharmaceuticals SA
  • Jiangsu Hengrui Medicine Co Ltd
  • KinDex Pharmaceuticals Inc
  • Spruce Biosciences Inc
Polycystic Ovarian Syndrome - Drug Profiles

(celecoxib + metformin hydrochloride + valsartan) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Drug for Polycystic Ovarian Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
elagolix sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
KDT-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
metformin hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Recombinant Protein to Agonize PEDF for Women's Health - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
saroglitazar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SHR-7280 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ThermoStem - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
tildacerfont - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Polycystic Ovarian Syndrome - Dormant Projects

Polycystic Ovarian Syndrome - Discontinued Products

Polycystic Ovarian Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
  • Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Polycystic Ovarian Syndrome, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by AbbVie Inc, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by Arkay Therapeutics LLC, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by Bayer AG, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by BioRestorative Therapies Inc, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by Cadila Healthcare Ltd, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals SA, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by KinDex Pharmaceuticals Inc, H2 2020
  • Polycystic Ovarian Syndrome - Pipeline by Spruce Biosciences Inc, H2 2020
  • Polycystic Ovarian Syndrome - Dormant Projects, H2 2020
  • Polycystic Ovarian Syndrome - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Polycystic Ovarian Syndrome, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Arkay Therapeutics LLC
  • Bayer AG
  • BioRestorative Therapies Inc
  • Cadila Healthcare Ltd
  • EffRx Pharmaceuticals SA
  • Jiangsu Hengrui Medicine Co Ltd
  • KinDex Pharmaceuticals Inc
  • Spruce Biosciences Inc
Note: Product cover images may vary from those shown
Adroll
adroll